

# PRODUCT INFORMATION

## CITRAVESCENT

### COMPOSITION

Sodium bicarbonate, citric acid, tartaric acid, lactose, sucrose as a flavouring agent.

### ACTIONS

Sodium bicarbonate and citric acid in Citravescent react in water to form sodium citrate. After absorption, sodium citrate is metabolised to sodium bicarbonate which increases the alkali reserve and renders the urine less acidic.

### INDICATIONS

Systemic and urinary alkalinisation where indicated in the relief of symptoms associated with urinary tract infections such as cystitis, pyelonephritis, urethritis; and in reducing the formation of uric acid and cystine calculi. Citravescent may increase the effectiveness of sulphonamide antibiotics in the treatment of urinary tract infection. Acid indigestion or heartburn.

### CONTRAINDICATIONS

Renal failure or hypernatraemia; in conjunction with hexamine mandelate or hexamine hippurate therapy because an acid urine is needed; patients on sodium restriction diet.

### WARNINGS

A prolonged high sodium intake can induce hypertension in susceptible individuals.

### PRECAUTIONS

Hypertension; peripheral and pulmonary oedema; low urine output; and toxæmia of pregnancy. Caution is advised in overt and occult cardiac failure.

### DOSAGE AND ADMINISTRATION

1 to 2 sachets in half a glass of cold water three or four times daily.

### PRESENTATION

Sachets 4g: 25's and 28's.

### POISON SCHEDULES

Nil.

### SPONSOR

sanofi-aventis australia Pty Ltd  
12-24 Talavera Road  
Macquarie Park NSW 2113  
AUSTRALIA

### DISTRIBUTED BY

iNova Pharmaceuticals (Australia) Pty Limited  
9-15 Chilvers Road  
Thornleigh NSW 2120  
AUSTRALIA

[Citavescent Product Information was Grandfathered  
and has not been evaluated by the Therapeutic Goods Administration]

(Date of most recent amendment: 12 September 2007)